<DOC>
	<DOCNO>NCT01918488</DOCNO>
	<brief_summary>The purpose study determine whether diuretic drug call amiloride capable increase renal salt excretion thereby decrease blood pressure diabetic patient kidney disease . Our hypothesis state amiloride capable reduce blood pressure patient thus decrease cardiovascular risk associate diabetic kidney disease .</brief_summary>
	<brief_title>Increased Activity Renal Salt Transporter ( ENaC ) Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Epithelial Sodium Channel Blockers</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>Type 1 diabetes Negative pregnancy test inclusion take contraceptive medication One group diabetic nephropathy overt proteinuria One normoalbuminuric group without nephropathy Creatinine clearance &gt; 40 ml/min Type 2 diabetes Receiving amiloride , glucocorticoid , aldosterone spironolactone Clinically relevant organic systemic disease include malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Diabetic Nephropathies</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Epithelial Sodium Channels</keyword>
	<keyword>Epithelial Sodium Channel Blockers</keyword>
	<keyword>Amiloride</keyword>
</DOC>